Search

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

84.61 -1.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.39

Massimo

85.31

Metriche Chiave

By Trading Economics

Entrata

-23M

-206M

Vendite

1.6M

19M

EPS

-1.67

Margine di Profitto

-1,064.485

Dipendenti

673

EBITDA

11M

-169M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.32% upside

Dividendi

By Acuity

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.4B

12B

Apertura precedente

85.97

Chiusura precedente

84.61

Notizie sul Sentiment di mercato

By Acuity

100%

0%

326 / 342 Classifica in Healthcare

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 lug 2026, 23:06 UTC

News

PepsiCo shares are lower in after-market hours following a downgrade to Hold by Citi, with the price target reduced to $145 from $170.

10 lug 2026, 23:01 UTC

News

Cognizant Technology Solutions received court approval for a $5.5 million settlement in a stockholder lawsuit, with shares trading higher in after-market hours.

10 lug 2026, 20:13 UTC

ETF Constituents
News
Correlated Moves

Vanguard Large-Cap ETF is trading lower in after-market hours, influenced by slight losses in top holdings META, AAPL, ABBV, MA, and NVDA.

10 lug 2026, 20:07 UTC

News
Correlated Moves

Ethereum is gaining as Circle Internet Group receives approval for a national trust bank, boosting interest in digital assets amid geopolitical tensions.

10 lug 2026, 20:07 UTC

News

Costco Wholesale shares are higher today, recovering from earlier losses despite concerns over moderating growth and sustainability amid easing fuel prices.

10 lug 2026, 20:07 UTC

News
Social Media

Micron Technology shares are lower amid a semiconductor sector selloff, despite announcing over $250 billion in U.S. investment for AI memory chips.

10 lug 2026, 20:07 UTC

News
Social Media
Event

Netflix Inc shares are lower amid concerns about declining subscriber engagement. The company is exploring strategies to enhance viewer interest, including live TV channels.

10 lug 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher as Circle Internet Group gains approval for a national trust bank focused on digital asset custody services. Ethereum also shows notable increases.

10 lug 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher since Thursday's close, supported by Circle Internet Group's approval for a national trust bank focused on digital asset custody services.

10 lug 2026, 20:07 UTC

Correlated Moves
News

Ethereum is gaining amid increased market interest following Circle Internet Group's trust bank approval. Geopolitical tensions are also driving investors toward cryptocurrencies.

10 lug 2026, 20:06 UTC

News

Autodesk Inc shares are lower today following a negative report from StockStory, which advises avoiding the stock due to slower revenue growth and high payback periods.

10 lug 2026, 20:06 UTC

News

United Airlines shares are lower amid concerns following Delta's strong earnings report, which raised expectations for upcoming results but highlighted pricing power challenges.

10 lug 2026, 20:06 UTC

Correlated Moves
Social Media
News

Applied Materials shares advance as Needham raises price target to $740 and Stifel lifts its target to $650, reflecting strong demand in the semiconductor sector.

10 lug 2026, 20:03 UTC

News
Social Media

NVIDIA shares are higher today as Morgan Stanley reaffirms its Overweight rating and U.S. eases AI chip export curbs to the UAE.

10 lug 2026, 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

10 lug 2026, 20:02 UTC

News
Social Media

Fox Corp shares are higher, supported by record FIFA World Cup viewership and an upgrade to Buy from Rothschild Redburn, raising the price target to $71.

10 lug 2026, 20:01 UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

10 lug 2026, 19:56 UTC

Social Media
News

Dollar Tree shares are higher after a positive UBS assessment, signaling an inflection point for the retailer amid cautious market sentiment ahead of key economic data.

10 lug 2026, 19:51 UTC

Social Media
News

Take-Two Interactive is under pressure amid sector weakness, with a recent report advising against the stock due to limited cash flow and declining sales projections.

10 lug 2026, 19:47 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Small-Cap ETF is lower amid ongoing geopolitical tensions and declines among key holdings, including SRPT, AXON, NTRA, LAMR, and IONS.

10 lug 2026, 19:47 UTC

News
Social Media

Tesla Inc's stock is higher, supported by increased buying interest and strong Model Y sales in China, with shares reaching an intraday high of $407.85.

10 lug 2026, 19:47 UTC

News

PayPal Holdings Inc is gaining momentum, driven by strong performance in Venmo and Braintree, alongside a clearer operational framework under CEO Dan Schulman.

10 lug 2026, 19:47 UTC

News
Social Media

Intel Corp's stock is lower as AMD's data center revenue outpaces Intel's, raising investor concerns amid ongoing profitability challenges.

10 lug 2026, 19:47 UTC

News

Qualcomm shares are lower at about $188.81 amid mixed options sentiment and a decline in implied volatility ahead of the upcoming earnings report.

10 lug 2026, 19:47 UTC

Correlated Moves
Social Media
News

Broadcom shares are lower despite a $30 billion agreement with Apple to produce custom silicon components through 2031, amid broader semiconductor industry concerns.

10 lug 2026, 19:46 UTC

News
Social Media

Rothschild Redburn upgraded Fox Corp to Buy, raising the price target to $71. The stock remains higher since Thursday's close despite earlier session pullbacks.

10 lug 2026, 19:46 UTC

News

American Airlines Group faces challenges ahead of its earnings report, with shares declining amid cautious sentiment following Delta Air Lines' strong Q2 performance.

10 lug 2026, 19:41 UTC

Macro News
ETF Constituents
News

FXI is trading higher following Shein's Hong Kong IPO approval, boosting confidence in Chinese equities. Key holdings XIACY and TCOM also show notable returns.

10 lug 2026, 19:36 UTC

News

CSX shares rise on TD Cowen, JP Morgan upgrades ahead of Q2 report.

10 lug 2026, 19:36 UTC

News
Social Media

Microsoft shares advanced after Argus reaffirmed a Buy rating, lowering the price target to $510. The stock remains near the upper end of its one-month range.

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

26.32% in crescita

Previsioni per 12 mesi

Media 107.21 USD  26.32%

Alto 140 USD

Basso 83 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

13

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

326 / 342 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
help-icon Live chat